Silencing of MAP3K7 and the MAP3K7 inhibitor reduced the proliferation of primary HCC cells, including 71T (HBV-negative, HCV-positive) and 89T (HBV-positive, HCV negative) cells (Figures 5G,H). This evidence concerns the gene MAP3K7 and hepatocellular carcinoma.